These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2571616)

  • 21. Clinical applications of alpha 1-receptor blockade: terazosin in the management of hypertension. Introduction.
    Rosenthal J; Kyncl JJ
    J Clin Pharmacol; 1993 Sep; 33(9):866-7. PubMed ID: 7901240
    [No Abstract]   [Full Text] [Related]  

  • 22. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials.
    Pool JL
    Am Heart J; 1991 Sep; 122(3 Pt 2):926-31. PubMed ID: 1678924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of pharmacokinetics and pharmacodynamics of adrenoceptor agonists and antagonists as antihypertensive agents.
    Louis WJ; McNeil JJ; Anavekar SN; Conway EL; Workman B; Howes LG; Drummer OH; Jarrott B
    J Cardiovasc Pharmacol; 1987; 10 Suppl 12():S100-3. PubMed ID: 2455158
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective alpha 1 inhibition with doxazosin in hypertensive smokers and non-smokers: haemodynamic and metabolic effects.
    Westheim A; Daae LN; Kierulf P; Brusletto B; Holme I; Syvertsen JO
    J Hypertens Suppl; 1990 Sep; 8(5):S41-6. PubMed ID: 1981076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The safety and efficacy of terazosin in the treatment of essential hypertension in blacks.
    Saunders E
    Am Heart J; 1991 Sep; 122(3 Pt 2):936-42. PubMed ID: 1678925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blood pressure and lipid lowering effects of terazosin.
    Rosenthal J
    J Hum Hypertens; 1989 Dec; 3 Suppl 2():85-9; discussion 90-1. PubMed ID: 2575179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-adrenergic blocking drugs in the management of benign prostatic hyperplasia: interactions with antihypertensive therapy.
    Tewari A; Narayan P
    Urology; 1999 Mar; 53(3 Suppl 3a):14-20; discussion 41-2. PubMed ID: 10094096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of terazosin therapy on blood pressure in men with benign prostatic hyperplasia concurrently treated with other antihypertensive medications.
    Lowe FC; Olson PJ; Padley RJ
    Urology; 1999 Jul; 54(1):81-5. PubMed ID: 10414731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sympathetic nervous system and hypertension. Therapeutic perspectives.
    Weber MA
    Am J Hypertens; 1989 Mar; 2(3 Pt 2):147S-152S. PubMed ID: 2564278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicenter trial of doxazosin in West Germany.
    Rosenthal J
    Am J Cardiol; 1987 May; 59(14):40G-45G. PubMed ID: 2884852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effects of doxazosin and atenolol on serum lipids and blood pressure in hypertensive smokers.
    Talseth T; Westlie L; Daae LN
    J Hypertens Suppl; 1990 Sep; 8(5):S47-51. PubMed ID: 1981077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-blocker therapy of hypertension. An unfulfilled promise.
    Khoury AF; Kaplan NM
    JAMA; 1991 Jul; 266(3):394-8. PubMed ID: 1676077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma.
    Miura Y; Yoshinaga K
    Am Heart J; 1988 Dec; 116(6 Pt 2):1785-9. PubMed ID: 2904751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.
    Luther RR; Glassman HN; Sperzel WD; Steinberg FJ; Horton JK; Jordan DC
    J Hypertens Suppl; 1986 Dec; 4(5):S494-7. PubMed ID: 2883273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of doxazosin and atenolol on blood pressure and blood lipids: a one-year, double-blind study in 228 hypertensive patients.
    Talseth T; Westlie L; Daae L; Vatle S
    Am Heart J; 1988 Dec; 116(6 Pt 2):1790-6. PubMed ID: 2904752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia.
    Mathur RP; Nayak S; Sivaramakrishnan R; Jain V
    J Assoc Physicians India; 2014 Sep; 62(9 Suppl):40-4. PubMed ID: 26245042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective alpha 1-adrenergic antagonists: therapeutically relevant antihypertensive agents.
    Graham RM
    Am J Cardiol; 1984 Jan; 53(3):16A-20A. PubMed ID: 6141721
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension.
    Frick MH; Cox DA; Himanen P; Huttunen M; Pitkäjärvi T; Pörsti P; Pöyhönen L; Pyykönen ML; Reinikainen P; Salmela P
    Am J Cardiol; 1987 May; 59(14):61G-67G. PubMed ID: 2884854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy and safety of terazosin.
    Cohen J
    J Clin Pharmacol; 1993 Mar; 33(3):272-8. PubMed ID: 8096524
    [No Abstract]   [Full Text] [Related]  

  • 40. The usefulness of alpha-adrenoceptor blockade in the treatment of hypertension.
    Warren JB; Dollery CT
    J Hypertens Suppl; 1988 Dec; 6(2):S43-9. PubMed ID: 2906700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.